^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Undisclosed CISH inactivated TIL

i
Other names: Undisclosed CISH inactivated TIL, CISH CRISPR TIL, tumor-infiltrating lymphocytes
Associations
Trials
Company:
Intima Biosci, University of Minnesota
Drug class:
Immunomodulator, Cytokine-induced SH2 protein inhibitor
Related drugs:
Associations
Trials
11ms
Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer. (PubMed, NPJ Genom Med)
Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high...Immune cell deconvolution suggested that the hot nodule was enriched not only in CD8+ and CD4 + T lymphocytes, but also in M1 macrophages, activated NK cells, and γδ T cells compared to the cold nodule. This case highlights that MMRd/TMB-high PC can evolve to minimize an anti-tumor immune response, and nominates downregulation of antigen presentation machinery (HLA loss) as a potential mechanism of adaptive immune evasion in PC.
Journal • Mismatch repair • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
|
TMB-H • MSI-H/dMMR
|
Undisclosed CISH inactivated TIL
1year
Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299. (PubMed, JTO Clin Res Rep)
This was a cooperative group, single-arm, phase 2 trial enrolling patients with unresectable mesothelioma after progression on more than or equal to one pemetrexed-containing regimen...Activation of tumor-infiltrating lymphocytes in response to treatment was associated with a trend toward improvement in PFS...Further investigation of this regimen in mesothelioma with nonepithelioid histology may be warranted. Clinical Trial Information: NCT03502746.
P2 data • Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • Cyramza (ramucirumab) • pemetrexed • Undisclosed CISH inactivated TIL
over1year
Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model. (PubMed, Cancer Sci)
Past clinical trials of adjuvant therapy combined with interferon (IFN) alpha, fluorouracil, cisplatin, and radiation improved the 5-year survival rate of pancreatic ductal adenocarcinoma (PDAC)...Notably, IFN-OAd + chemotherapy + radiation remarkably suppressed tumor growth and induced a higher number of tumor-infiltrating lymphocytes without severe side toxic effects in an immunocompetent and adenovirus replication-permissive hamster PDAC model...IFN-OAd has the potential to overcome the barriers to clinical application of IFN-based therapy through its tumor-specific expression of IFN, induction of antitumor immunity, and sensitization with chemoradiation. Combining IFN-OAd with gemcitabine + nab-paclitaxel + radiation might be an effective and clinically beneficial treatment for PDAC patients.
Preclinical • Journal • Oncolytic virus
|
cisplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • Undisclosed CISH inactivated TIL
over1year
Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data. (PubMed, Clin Lung Cancer)
High TMB has a prognostic role in resectable lung ADC. The high TMB group had a poor outcome with AC, suggesting that this group may be better served with immune checkpoint therapy.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
TMB-H • PD-L1 negative • TMB-L • PD-L1 negative + TMB-L
|
cisplatin • Undisclosed CISH inactivated TIL
almost3years
Quantitative Analysis of Breast Cancer Tissue Composition and Associations with Tumor Subtype. (PubMed, Hum Pathol)
Similar associations were observed between immune infiltrate and tumor phenotypes. Quantitative digital image analysis of the breast cancer microenvironment showed significant associations with demographic characteristics and biological indicators of aggressive behavior.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Undisclosed CISH inactivated TIL
over3years
[VIRTUAL] Clinical Application of CRISPR Edited Tumor Infiltrating Lymphocytes in Gastrointestinal Cancer (ASGCT 2021)
Currently, two patients have received TIL infusion without evidence of acute adverse toxicity related to the cellular product. Clinical updates will be presented.
Clinical • Tumor-Infiltrating Lymphocyte • IO biomarker
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Undisclosed CISH inactivated TIL
over4years
[VIRTUAL] Immunophenotyping of tumor microenvironment to uncover the hidden clues for immunotherapy response in ovarian cancer (HAGO 2020)
We have enrolled over 40 women and have completed single cell RNA sequencing (scRNAseq), multiplex immunohistochemical assays, H&E scoring for tumor infiltrating lymphocytes (TILs) and NanoString molecular subtyping in 30 women... Single-cell RNA-seq is more reliable in identifying PD-1/ PD-L1 across cells than IHC assays. Single biomarker alone might not be predictive of treatment response. Our study is ongoing and we will categorize these patients into various subtypes based on presence or absence of multiple immune markers (PD-1/PDL-1, TILs, molecular subtypes, IHC assays) and will follow the disease course in these categories.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • PD-1 expression
|
Undisclosed CISH inactivated TIL